Processa Pharmaceuticals director buys 2,531 shares

Processa Pharmaceuticals, Inc. director and officer David Young bought additional common stock in an open-market transaction.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. director and officer David Young bought additional common stock in an open-market transaction. On June 30, 2026, he purchased 2,531 shares at $1.93 per share, bringing his direct holdings to 21,729 shares of common stock.

He also reports indirect ownership of common stock through several entities as of that date: 1,009 shares held by CorLyst, LLC, 432 shares held by Family Entities, and 1,242 shares held by the Young-Plaisance Revocable Trust.

Insider Trade Summary

Net Buyer: 2,531 shares

Net Buy 4 txns

Insider Young David

Role Pres. Research & Development

Bought 2,531 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,531	$1.93	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 21,729 shares (Direct); Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust); Common Stock — 432 shares (Indirect, By Family Entities); Common Stock — 1,009 shares (Indirect, By CorLyst, LLC)

Key Figures

Open-market purchase shares: 2,531 shares Purchase price: $1.93 per share Direct holdings after transaction: 21,729 shares +3 more

6 metrics

Open-market purchase shares 2,531 shares Common Stock bought on June 30, 2026

Purchase price $1.93 per share Price for June 30, 2026 open-market buy

Direct holdings after transaction 21,729 shares Common Stock held directly after June 30, 2026

Indirect holdings via CorLyst, LLC 1,009 shares Common Stock reported as indirectly owned

Indirect holdings via Family Entities 432 shares Common Stock reported as indirectly owned

Indirect holdings via Young-Plaisance Revocable Trust 1,242 shares Common Stock reported as indirectly owned

Key Terms

open-market purchase, indirect ownership, Common Stock, Form 4

4 terms

open-market purchase financial

"He purchased 2,531 shares at $1.93 per share in an open-market purchase."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"He also reports indirect ownership of common stock through several entities as of that date."

Common Stock financial

"He purchased 2,531 shares at $1.93 per share, bringing his direct holdings to 21,729 shares of common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"What did David Young report in his latest Form 4 for PCSA?"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did David Young report in his latest Form 4 for PCSA?

David Young reported buying 2,531 shares of Processa Pharmaceuticals common stock at $1.93 per share, increasing his direct holdings to 21,729 shares as of June 30, 2026.

At what price did David Young buy Processa Pharmaceuticals (PCSA) shares?

He bought common stock at $1.93 per share. This open-market purchase on June 30, 2026 added 2,531 shares to his direct ownership in Processa Pharmaceuticals.

How many Processa Pharmaceuticals shares does David Young now hold directly?

After the reported transaction, David Young directly holds 21,729 shares of Processa Pharmaceuticals common stock. This figure reflects his position following the 2,531-share open-market purchase on June 30, 2026.

What indirect Processa Pharmaceuticals holdings are associated with David Young?

Indirect holdings include 1,009 shares held by CorLyst, LLC, 432 shares held by Family Entities, and 1,242 shares held by the Young-Plaisance Revocable Trust, all reported as of June 30, 2026.

Is David Young’s latest PCSA Form 4 a buy or sell transaction?

It reflects a buy transaction. David Young executed an open-market purchase of 2,531 shares of Processa Pharmaceuticals common stock at $1.93 per share on June 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		P		2,531	A	$1.93	21,729	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								1,009	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)